If you have a burning desire to respond to a paper published in Sex Transm Infect, why not make use of our “eLetters” option?

Log on to the STI web site (www.stijournal.com), find the paper that interests you, click on [Abstract] or [Full text] and send your electronic response by clicking on “eLetters submit a response”.

Providing your letter isn’t libellous or obscene, it will be posted within seven days. You can view recent eLetters by clicking on “Read eLetters” on our homepage.

As before, the editors will decide whether to publish the eLetter in a future print issue.

Perforating chancre: any cause-effect relation with HIV infection?

Variation in clinical pictures of syphilis, when co-infected with HIV are well known.1 Normally, a classic Hunterian chancre heals within 1-2 weeks of treatment without scarring.2 Primary chancre, healing with perforation of the site, does not commonly occur.3 Here we report four patients with primary syphilis, in whom the chancre healed with perforation of the genitalia. Concomitant infection with HIV is presumed to be responsible for this destructive sequela.

Case 1
A 21 year old woman presented with a painless, indurated ulcer over the inner aspect of the left labia majora, along with some sized inguinal lymphadenopathy of 1 week’s duration. Dark ground microscopy (DGI) was positive for T. pallidum andVDRL titre was 1:64. Following treatment with penicillin, the ulcer healed slowly, leaving a perforation on the labia majora.

Case 2
A 20 year old unmarried male patient with high risk behaviour presented with a painless indurated ulcer over the dorsal aspect of the prepuce and unilateral inguinal lymphadenopathy. DGI was positive for T. pallidum andVDRL titre was 1:32. He had a history of genital ulceration and was treated for suspected lymphogranuloma venereum. Following treatment with penicillin, the ulcer healed at a slower pace leaving a large perforation on the prepuce (fig 1).

Case 3
A 23 year old unmarried man, with a history of repeated unprotected exposure to commercial sex workers, presented with a painless, indurated ulcer on the dorsal prepuce, multiple genital mollusca contagiosa, and genital warts. VDRL was 1:32. He was treated with penicillin.

Comment
Gram stained smears from the ulcers and culture for aerobic and anaerobic organisms were negative in first three cases. In all the four patients, ELISA for HIV was positive. Immune response to T. pallidum is primarily cell mediated.7 In an immunocompetent host with primary syphilis, CD4+CD8+ T lymphocyte ratio is high at the site of the chancre,8 which possibly prevents local multiplication of the organism. Consequent to the loss of local cellular immunity as a result of HIV infection there may be an enhanced ability of the organism to multiply locally, giving rise to larger and deeper ulcers which are slower to heal. This fact has been demonstrated experimentally in animal models.9 Studies exploring the correlation of CD4+ T cell count and stage of HIV infection with this altered manifestation of primary syphilis should be undertaken. This might show the impact of HIV infection on the clinical severity of primary chancre.

Figure 1 Perforation of prepuce.

Bilateral inguinal lymphadenopathy was present. DGI from the ulcer was negative andVDRL was 1:64. Following penicillin therapy, it healed with perforation of the prepuce.

Case 4
A 45 year old married man with high risk behaviour presented with a large perforation on the lateral side of the shaft of the penis. He gave a history of a painless ulcer on the same site about 1 month earlier. At presentation, hisVDRL was 1:32. He was treated with penicillin.

Comment
Sideroqueratotic keratosis, blood smears and acid fast stain microscopy. DGI was negative from the ulcer. In all the four cases, ELISA for HIV was positive. Two litres of bile were aspirated per day. His body mass index (BMI) fell to less weight. His body mass index (BMI) fell to

References

Accepted for publication 10 October 2002

Superior mesenteric artery syndrome in an HIV positive patient

A 27 year old HIV positive man with a CD4+ lymphocyte count of 26 cells x10^3/l presented with a 2 week history of progressive left sided weakness, vomiting, and weight loss. A computed tomograph (CT) brain scan demonstrated ring lesions bilaterally in the basal ganglia. Toxoplasma serology was positive at a titre of 1:256 and treatment for cerebral toxoplasmosis commenced. His weakness responded to therapy but vomiting continued despite antiemetics. An ultrasound scan demonstrated an enlarged, dilated stomach, dilated first and second parts of the duodenum, and an obstruction at the level of the third. Barium studies confirmed these findings but also demonstrated prominent peristalsis in the second part of the duodenum and an abrupt cessation of flow to barium in the middle of the third (fig 1). Some flow of barium into the jejunum was noted when the patient was turned prone. An abdominal CT scan demonstrated a reduction in the angle between the superior mesenteric artery and the aorta (fig 2). A diagnosis of superior mesenteric artery (SMA) syndrome was considered. Two litres of bile were aspirated per nasogastric tube daily and he continued to lose weight. His body mass index (BMI) fell to

Figure 1 Image from barium meal series. The proximal duodenum is dilated. There is an abrupt calibre change (arrow) in the third part where the superior mesenteric artery crosses. Distinct peristalsis was seen in this region during the study.
wasting conditions, prolonged immobilisation and weight loss resulting in a reduction of
muscle mass. This is often because of sudden, severe ileus, and Wilkie’s syndrome. First described
by Rokitansky in 1842, frequency of reports vary with time and geographic location. This syndrome,
in the setting where the prevalence of another STI, is related than differences in the rate of partner
disease control—that is, routinely linking nucleic acid amplification test-
ing for C trachomatis with the Pap smear, could also be considered.

Conflict of interest: None.

F J Bowden
Australian National University and Canberra Sexual Health Centre, PO Box 11, Woden ACT,
Australia 2605, frank.bowden@act.gov.au

References
1 Tapsall JW, Pugill J, Smith DD. Trichomonas vaginalis infections in Sydney: laboratory diagnosis and prevalence. Med J Aust
1997; 278: 117–18.
4 Adad SJ, de Lima RV, Sawan ZT, et al. Frequency of Trichomonas vaginalis, Candida and Gardnerella vaginalis infection in
5 Malek D, Straton JA. Effects and sustainability of a cervical screening program in remote Aboriginal Australia. Aust NZ J Public Health

Accepted for publication 16 December 2002

The HIV/AIDS epidemic in Ukraine: stable or still exploding?

A recent article published in Sexually Transmitted Infections presented evidence suggesting that the HIV/AIDS epidemic in Ukraine had peaked in 1997 and has since declined. The world has only recently awoken to the threat of a widespread HIV/AIDS epidemic in east-
ern Europe, including projections of an

or nasogastric decompression is often difficult
because of severe gastric dilatation. Duodenal-
jejunitis or gastric-jejunitis are the surgical
procedures of choice when medical therapy fails.1–3 Our patient did not experience immediate symptomatic relief through sur-
gery but did achieve rapid weight gain via
jejunal feeding. We report the first case of
SMA syndrome in a patient with AIDS. The
spread of HIV worldwide and its association with severe wasting makes this an important
differential diagnosis for the clinician.

R Stumpfle, A R Wright, J Walsh
St Mary’s Hospital, Praed Street, London W2 1NY, UK

Correspondence to: Dr Richard Stumpfle,
Department of Anaesthetics, Northwick Park
Hospital, Watford Road, Harrow, Middlesex
HA1 3UJ, UK; rstumpfle@doctors.net.uk

12 and total parental nutrition was intro-
duced for 6 weeks after which an exploratory
laparotomy was performed. An anterior gas-
trojejunitis was made and a jejunal feed-
tube inserted into the collapsed proximal small bowel. The patient recovered postopera-
tively and was able to vomit after meals. After 4 weeks his BMI increased to 15, vomit-
tively but continued to vomit after meals.

trojejunostomy was made and a jejunal feed-

Accepted for publication 16 December 2002

Was the Papanicolaou smear responsible for the decline of Trichomonas vaginalis?

There has been a dramatic decline in the prevalence of trichomomiasis in Australia over
the past 30 years. In 1979, 17.8% of women attending a Sydney STI clinic had Trichomonas
vaginalis infection.1 By 1998 less than 1% of non-Indigenous women presenting to family
planning and STI clinics in another part of the

References

Accepted for publication 16 December 2002

Was the Papanicolaou smear responsible for the decline of Trichomonas vaginalis?

There has been a dramatic decline in the prevalence of trichomomiasis in Australia over
the past 30 years. In 1979, 17.8% of women attending a Sydney STI clinic had Trichomonas
vaginalis infection.1 By 1998 less than 1% of non-Indigenous women presenting to family
planning and STI clinics in another part of the
epidemic in Russia of between 6–11% by 2010, and the potential for economic decline and geopolitical instability: HIV trends in Ukraine, with many of the same socioeconomic characteristics and risk factors found in Russia—namely, large numbers of injecting drug users (IDUs), an expanding sex industry, internal and external migration, poor access to health care, general economic and social upheaval, and a recent explosive syphilis epidemic—must therefore be examined closely. Could Ukraine present a model for Russia in terms of controlling the HIV epidemic, or does Ukraine in fact represent an ongoing epidemic inadequately described by official statistics?

The first indication that perhaps the data presented by Mavrov and Bondarenko might reflect the ongoing HIV epidemic in Ukraine is the apparent contradiction in table 1, which reports the prevalence of HIV among select groups in 1998 and 1999. While HIV prevalence for “all populations” declined, every subpopulation increased, except for a decline from 0.07% to 0.064% among blood donors. Prevalence among pregnant women, who reflect the likely future of the epidemic, increased by 33%.

Current official statistics in Ukraine simply do not reflect the current status of the epidemic, and, importantly, do not reflect the likely future course of the epidemic. As Mavrov and Bondarenko report, the majority of new HIV cases continue to be among IDUs. This population is wary of the healthcare sector, as the acknowledgement of drug use to a healthcare provider leads to obligatory registration and confinement for treatment, possible job loss, loss of one’s driving licence, and criminal prosecution. Kobyschka reported that only 5% of IDUs were covered by the current system of HIV surveillance. Rather than the 8.6% prevalence reported by Mavrov and Bondarenko among IDUs, cross sectional studies have shown prevalence of between 18% and 64% (table 1).

Behavioural factors also argue against the likelihood of a stable epidemic in Ukraine. In a study of female sex workers (FSWs) in Odessa conducted in 1997 and 1999, the percentage of FSWs reporting always using condoms declined (from 48% to 40%) in 1999. The national reproductive health survey found that 27% of women reported condom use at last spermicidal pilling a study into the sexual health of adult performers. It will be of particular interest to see whether sexual health care can be provided for this group within the bounds of the NHS or whether they, like their American counterparts, will choose to rely on private clinics to provide them with care and information.

D Cawley, R Nandwani

The Sandyford Initiative, Glasgow, UK

Correspondence to: Declan Cawley@gascenm.scot.nhs.uk

Table 1

<table>
<thead>
<tr>
<th>Site</th>
<th>HIV prevalence (%)</th>
<th>Sample size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poltava</td>
<td>41.7</td>
<td>259</td>
</tr>
<tr>
<td>Donetsk</td>
<td>39.7</td>
<td>252</td>
</tr>
<tr>
<td>Kryvyi Rig</td>
<td>28.1</td>
<td>249</td>
</tr>
<tr>
<td>Odessa</td>
<td>64.0</td>
<td>293</td>
</tr>
<tr>
<td>Simferopol</td>
<td>27.2</td>
<td>261</td>
</tr>
<tr>
<td>Kharkiv</td>
<td>17.8</td>
<td>250</td>
</tr>
</tbody>
</table>


References


Accepted for publication 16 December 2002

Raising awareness of UK GUM clinic activities

In their recent letter on the sexual health issues which face performers in the adult entertainment industry, Gabrielsen and Barton highlight the current lack of coherent sexual health infrastructure for this population in the United Kingdom. The work of the Adult Film Stars Health Partnership Project in north London (n=367), and GPs recruited for the Chlamydia Partnership Project in north London (n=65) (a randomised trial of health adviser led partner notification for primary care patients) were invited to complete a short questionnaire. The response rate was 56%.

Of the 242 respondents, 86% considered testing for genital Chlamydia trachomatis infection in women to be a GP role, while 60.7% considered that partner notification is not a role of the GP. 90.5% of respondents thought that one or more patients had had a positive test at the practice in the preceding year.

Among GPs who had recently been involved in managing chlamydia, 82.5% always or sometimes managed the patient wholly within primary care; 70.1% said they “always” or “sometimes” managed patients. However, only 53% of respondents thought that one or more patients had had a positive test at the practice in the preceding year.

Partner notification in primary care

In the past decade, chlamydia tests have become more widely available in primary care, and many female patients are now diagnosed and treated in this setting. Therefore, bearing in mind the complex issues which face performers in the adult entertainment industry, Gabrielsen and Bar-
Genitourinary Medicine, while 17.3% specified an inadequate course. Dosage or duration could not be ascertained in 12.7% of responses. This suggests substantial improvement in the past few years, although our study probably over-represents GPs already trained, since it did not fully exploit the extent of good practice.

Our study suggests that GPs already willingly take on an important role in diagnosing and managing genital chlamydia infection. They agree overwhelmingly that partner notification is the main difficulty in managing these patients. However, there is little evidence of follow up strategies designed to minimize re-infection risk, as in previous studies," and the majority of GPs consider that partner notification is not their role. The latter view probably explains why the majority manage partner notification by simply telling the patient to deal with it, without support or follow up.

If testing in primary care continues to increase without adequate support for partner notification, much of the resource used in testing women will be wasted. The announcement of pilot sites for chlamydia testing in primary care is to be welcomed. However, support for GPs in partner notification should not wait for the roll out of a national programme, as many patients diagnosed in primary care are already at risk of re-infection and onward transmission.

Acknowledgements

We are grateful to NoCT eN and Trent Focus (primary care research networks) for facilitating the Chlamydia Partnership Project. Dr Jackie Cassell was supported on a Health Services Research Training Partnership Project. Dr Jackie Cassell was supported on a Health Services Research Training Partnership Project. We wish to highlight the role of circumcision in extensive genital warts involving prepuce, which were refractory to the conventional treatment. A 50 year old patient presented to us with genital warts for duration of 4 years. On examination, lesions were in the form of sessile, filiform, and papular keratotic verrucous lesions present involving both outer and undersurface of almost whole of the prepuce (fig 1). These lesions were treated by us and in the past by various doctors with topical podophyllin, trichloroacetic acid cautery, electrosurgery, etc, for periods ranging from weeks to months with only minimal response, with the lesions coming back. The patient had some difficulty in retraction of the prepuce and was psychologically disturbed. The patient otherwise was healthy with no evidence of any other disease. Considering the extensive involvement of prepuce and refractory nature to various treatments, circumcision was performed. Histopathological examination of the excised tissue showed changes consistent with warts without any cellular atypia. Surgical wound healed well in a week with no complications.

Extensive genital warts with evidence of keratination are often refractory to podophyllin, podophyllotoxin, and cryotherapy, etc, and are best dealt with surgically or by topical 5-fluorouracil cream. Scissor excision has been mentioned in the treatment of sebaceous lesions over the shaft of penis, labia majora, and perianal warts. However, circumcision for extensive preputial warts finds no place in the list of treatments for genital warts in men. In addition to the psychological morbidity, larger and more numerous warts can cause discomfort, and particularly involving prepuce can cause phimosis, secondary infection, and marital disharmony and considerable anxiety in the sexual partner. Globally, approximately 25% of the male population is circumcised for religious, cultural, medical, or parental choice reasons. However, controversies surround its benefits and protective effects against STDs. For genital warts, one study has reported a significant association with the lack of circumcision. 6

Substantive evidence supports the premise that circumcision protects males from HIV infection, cervical cancer, non-genital tract infections, and ulcerative STDs. 4 Although it may be debatable to recommend circumcision to reduce the risk of acquiring any one of the other STDs/HIV infection in isolation, taken together however the psychological and sexual discomforts for the patients and their sexual partners with recurrent/persistent extensive preputial warts, circumcision should be tried.

S Dogra, B Kumar

Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence to: Professor Bhushan Kumar, Department of Dermatology Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India, kumarbhushan@hotmail.com

References

3 McMillan A. The management of difficult anogenital warts. Sex Transm Infect 1997;75: 192–4
Accepted for publication 16 January 2003

Treatment of Candida glabrata using topical amphotericin B and flucytosine

We read with interest the article by White and colleagues on the treatment of Candida glabrata using topical amphotericin B and flucytosine because this infection can prove difficult to treat. 1 We have since used this treatment on a 28 year old woman with a 10 year history of recurrent candida.

The woman first attended our department complaining of a recurrent itchy white discharge. She had received numerous courses of antifungals including topical clotrimazole, oral itraconazole, and fluconazole with no relief. Vaginal swabs were positive for C glabrata and she was treated with nystatin pessaries 200 000 units at night for 14 nights. Culture was still positive for C glabrata at follow up 4 weeks later so she was advised to continue with nystatin pessaries for a further 4 weeks. On review she felt her symptoms were slightly better but she found the pessaries were not dissolving so she was switched to nystatin cream 200 000 units by
vagina for 28 nights. After this course of treatment she remained symptomatic and positive on culture for *C. glabrata*. Following the success with topical fluconazole and amphotericin B in the above article our pharmacist obtained this preparation. The patient was given amphotericin 100 mg plus fluconazole 1 g in Aquagel in a total 8 g dose, which was given by vaginal applicator nightly for 14 nights. She was reviewed 2 and 6 weeks after finishing treatment, her symptoms had greatly improved and cultures for yeast were negative on both occasions.

White’s paper described the successful treatment of three patients with candidiasis using topical amphotericin B and fluconazole. Our patient makes up the fourth case of successful eradication of refractory vaginal *C. glabrata* using this combination which, like the other cases, was very well tolerated.

S Shann, J Wilson

Department of Genitourinary Medicine, Sunnybank Wing, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK

Correspondence to: Dr S Shann, Department of Genitourinary Medicine, Sunnybank Wing, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK; siobhan.mcmyler@leedsth.nhs.uk

Reference


Accepted for publication 27 February 2003

---

**BOOK REVIEW**


I judge this is a jewel of a book, although you would not think so from my comments in the next paragraph.

My initial reaction was one of intense irritation. The preface stated that the intention was to “review the state of the art . . . of this rapidly emerging . . . field.” A bold promise for which tight editorial time lines and up to date references would be essential. Yet, even though the book was published in 2002, there were very few references from 2001 or even from 2000 in some chapters. To take as one particularly bad example, the chapter dealing with the immunotherapy of HIV had only one reference as recent as 2000, and all the rest were from the last millennium.

It is a credit to the book’s other talents that my bad humour was rapidly dissipated. The introductory chapters were, quite simply, a pleasure. The basis of humoral immunity was a clear rendition of the area, and the chapter on the principles of cellular immunology was as good, and as enjoyable an introduction to the field as you could get. The final introductory chapter, on mucosal defences, maintains the high standards set by the first two.

The remainder of the book is divided into three sections covering the molecular basis for immunotherapy, immunotherapy for HIV infection, and immunotherapy for other infectious diseases. Each of these three sections provides a good review of the major issues. The molecular basis of for immunotherapy contains an excellent chapter on the role of dendritic cells, and usefully explains how their crucial role in immune defences might be utilised for immune therapy. The chapter on cytokines sheds light on an area which is too complex or obtuse for many.

The section on immunotherapy for HIV infection covers in turn the basis for immunotherapeutic HIV vaccines, passive immunotherapy, and gene therapy. There are some notable omissions dictated by the presumed delay between the research for each chapter, and publication of the book. For instance, RNA interference, sometimes known as post-transcriptional gene silencing, is currently being investigated as a possible major therapeutic strategy for the future. True, the problem of delivery to the target cells still has to be solved, but for RNA interference to be left out dates the book already. Similarly many of the viral and bacterial vectors for vaccine delivery worked on the past few years, such as adenovirus, and salmonella, to name just two, are not included. Even those that are, such as canarypox, are not included in the index. Which leads to my final criticism before summing up—the index is entirely inadequate and mitigates strongly against using this as a book of reference.

So in conclusion, this book represents a flawed gem. Viewed from a certain light it is illuminating, a joy to behold. From other angles, the imperfections are all too obvious. None less the, for a physician or scientist working in the field of infectious diseases or related areas such as STDs or HIV, it provides an introduction to the field of immunotherapy which is both accessible and enjoyable. Read it within the next couple of years before it begins to date further and it will be time well invested. For a specialist in the field it has limited value, except to recommend to trainees or newcomers.

If the editor decides to bring out another edition, he should somehow do the near impossible for multiauthored texts, and ensure they are all up to date. Oh, and also invest in a professional indexing service. Then, there really will be a precious jewel.

Barry S Peters

---

**NOTICES**

**International Herpes Alliance and International Herpes Management Forum**

The International Herpes Alliance has introduced a web site (www.herpessalliance.org) where patient information leaflets can be downloaded. Its sister organisation the International Herpes Management Forum (web site: www.IHMF.org) has launched new guidelines on the management of herpesvirus infections in pregnancy at the 9th International Congress on Infectious Disease (ICID) in Buenos Aires.

**Pan-American Health Organization, regional office of the World Health Organization**

A catalogue of publications is available online (www.paho.org). The monthly journal of PAHO, the Pan American Journal of Public Health, is also available (subscriptions: pubsvc@tsp.sheridan.com).

**Australasian Sexual Health Conference: Tango down South—2003!**

4–7 June 2003, Christchurch Convention Centre, New Zealand

Further details: Dart Associates (tel: +02 9418 9396/97; email: dartcon@mpx.com.au; web site: http://www.acslhp.org.au).

**7th European Society of Contraception Seminar**


The 7th ESC Seminar on contraceptive practice in Europe: differences in availability and accessibility, will be held in Budapest Hungary. The main themes are availability and accessibility of: (1) contraceptive methods, (2) emergency contraception, (3) testing and treatment of sexually transmitted infections, and (4) abortions.

Further details: ESC Central Office, Eussenstraat 77, B-1740 Ternat, Belgium (tel: +32 2 582 0832; fax: +32 2 582 5515; email: esccentraloffice@contraception-esc.com; website: www.contraception-esc.com).